An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Copanlisib (Primary) ; Itraconazole
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 04 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2018 Planned primary completion date changed from 28 Jun 2018 to 27 Apr 2018.
- 23 Jun 2017 Planned number of patients changed from 58 to 46.